CLINICAL_TRIALS
trial_result
· 2014-02-20
Clinical Trial Update: Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Summary
Phase 2 trial evaluating bortezomib and lenalidomide in relapsed or refractory mantle cell lymphoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-02-20